BD enrolls first patient in registry study for PAD treatment device

NEW YORK - BD (Becton, Dickinson and Company) (NYSE:BDX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $55.6 billion, announced Thursday it has enrolled the first patient in its XTRACT Registry study, designed to evaluate real-world performance of the Rotarex Catheter System in treating peripheral artery disease (PAD). According to InvestingPro data, the company maintains a strong financial health rating and has demonstrated consistent revenue growth, reaching $21.4 billion in the last twelve months.

The first patient was enrolled on September 29 under Dr. Kousta Foteh, Chief of Vascular Surgery at Vital Heart & Vein medical practice. The prospective, multi-center registry aims to collect data on the device’s performance in clinical settings.

"This first case is similar to what we commonly see in our clinic, where an artery is more than 70% occluded," Dr. Foteh said, according to the company’s press release.

The registry is expected to enroll up to 600 patients across approximately 100 U.S. clinical sites. Participants will undergo follow-up evaluations at 30 days, six months, and 12 months after their procedures to assess both safety and effectiveness of the catheter system.

The Rotarex Catheter System functions as both an atherectomy and thrombectomy device, designed to remove plaque and thrombus from peripheral arteries using three mechanisms of action.

PAD affects more than 21 million Americans and over 200 million people worldwide, according to the company. If left untreated, the condition can increase risk of cardiovascular complications and lower limb amputation.

The study is being led by co-principal investigators Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon.

This announcement is based on a press release statement from BD.

In other recent news, Becton Dickinson reported impressive fiscal third-quarter results for 2025, with revenue reaching $5.5 billion, slightly surpassing the projected $5.49 billion. The company achieved an adjusted earnings per share of $3.68, exceeding the consensus estimate of $3.40. Piper Sandler responded to these strong results by raising its price target for Becton Dickinson stock to $200, while maintaining a Neutral rating. Meanwhile, RBC Capital initiated coverage of Becton Dickinson with a Sector Perform rating and a price target of $211, as the company plans a significant restructuring involving the spin-off and merger of its Biosciences and Diagnostics units with Waters in 2026.

In addition to financial performance, Becton Dickinson has been active in forming strategic partnerships. The company announced a collaboration with Opentrons Labworks to integrate robotic liquid-handling capabilities into its single-cell multiomics instruments, aiming to enhance research efficiency. Another partnership with Henry Ford Health will implement pharmacy automation technology to facilitate 24/7 prescription pick-up services. These developments highlight Becton Dickinson’s ongoing efforts to innovate and expand its technological capabilities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.